Literature DB >> 2523785

The action profiles of human NPH insulin preparations.

A A Starke1, L Heinemann, A Hohmann, M Berger.   

Abstract

The complete time-action profiles of four subcutaneously injected human NPH insulin preparations (Protaphane HM/Novo; Insulatard Human/Nordisk; Huminsulin Basal/Eli Lilly; Basal H-Insulin/Hoechst) have been investigated by means of the euglycaemic clamp technique (blood glucose 5.0 mmol l-1). Six normal male subjects were connected to a Biostator on five occasions in randomized order including a control study without insulin injection. A stable basal insulin level of about 10 mU l-1 was established by means of a low dose insulin infusion (0.1 mU kg-1 min-1) which subsequently suppressed C-peptide by 35 +/- 19% (mean +/- SD) to levels of around 0.3 nmol l-1. Twelve units of NPH insulin were injected subcutaneously into the abdominal wall and glucose infusion rates were monitored for 19 h. In the control study, the mean glucose infusion rate was 1.11 +/- 0.60 (range 0.32-1.95) mg kg-1 min-1. Maximal glucose infusion rates, reached 5-7 h after injection, were comparable (4.3-4.9 mg kg-1 min-1) for the four different preparations used. Glucose infusion rates returned to basal rates within the 19 h study period. Mean plasma free insulin levels peaked at 17.5-18.6 mU l-1 3-4.5 h after injection and returned to basal levels within 16 h. The time ranges of greater than 90, greater than 75, greater than 50, and greater than 25% of maximal insulin action (as estimated from glucose infusion rates) revealed no significant differences between the four insulin preparations tested. No significant insulin action was observed beyond 17 h after insulin injection of any preparation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523785     DOI: 10.1111/j.1464-5491.1989.tb01154.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  11 in total

1.  Glucose infusion rates during euglycaemic clamps do not precisely reflect action profiles of subcutaneously injected insulin.

Authors:  W Kerner; F S Keck; E F Pfeiffer
Journal:  Diabetologia       Date:  1991-01       Impact factor: 10.122

2.  Overnight versus 24 hours of continuous subcutaneous insulin infusion as supplement to oral antidiabetic drugs in type 2 diabetes.

Authors:  Tina Parkner; Torben Laursen; Jian-Wen Chen; Marianne K Møller; Henrik F Thomsen; Christina Jørgensen; Jørgen S Smedegaard; Torsten Lauritzen; Jens S Christiansen
Journal:  J Diabetes Sci Technol       Date:  2007-09

3.  Action profiles of fast onset insulin analogues.

Authors:  L Heinemann; A A Starke; L Heding; I Jensen; M Berger
Journal:  Diabetologia       Date:  1990-06       Impact factor: 10.122

4.  Fitting nonlinear regression models with correlated errors to individual pharmacodynamic data using SAS software.

Authors:  R Bender; L Heinemann
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

Review 5.  Intensive diabetes management in pediatric patients.

Authors:  B Buckingham; B Bluck; D M Wilson
Journal:  Curr Diab Rep       Date:  2001-08       Impact factor: 4.810

6.  Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects.

Authors:  F J Ampudia-Blasco; L Heinemann; R Bender; A Schmidt; T Heise; M Berger; A A Starke
Journal:  Diabetologia       Date:  1994-07       Impact factor: 10.122

Review 7.  Equivalent Recombinant Human Insulin Preparations and their Place in Therapy.

Authors:  Juergen Sandow; Wolfgang Landgraf; Reinhard Becker; Gerhard Seipke
Journal:  Eur Endocrinol       Date:  2015-04-11

8.  Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

Authors:  K Hermansen; P Fontaine; K K Kukolja; V Peterkova; G Leth; M A Gall
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

9.  Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study.

Authors:  Yi Tao; Mingxue Zhu; Junliang Pu; Peilin Zhang; Lei Wan; Chengyong Tang
Journal:  Front Pharmacol       Date:  2021-12-02       Impact factor: 5.810

10.  Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.

Authors:  P C Bartley; M Bogoev; J Larsen; A Philotheou
Journal:  Diabet Med       Date:  2008-04       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.